## June 7, Day 1

### Introduction and CPE credit requirements
- **Title**: Introduction and CPE credit requirements
- **Speaker**: Carriann Smith, PharmD, Associate Professor of Pharmacy Practice
- **Credit**: 7:45-8:00
- **Objectives**:
  1. Describe Butler’s partnership with the Indiana Department of Insurance.
  2. Review non-discrimination requirements and applicable CMS tools.
  3. Discuss MHPEAE and application to pharmacy practice.

### BU partnership with the Indiana DOI
- **Title**: BU partnership with the Indiana DOI
- **Speaker**: Carriann Smith, PharmD, Associate Professor of Pharmacy Practice
- **Credit**: 1/2
- **Timing**: 8:00-8:30
- **Objectives**:
  1. Describe Butler’s partnership with the Indiana Department of Insurance.
  2. Review non-discrimination requirements and applicable CMS tools.
  3. Discuss MHPEAE and application to pharmacy practice.

### New Drugs I: Drugs
- **Title**: New Drugs I: Drugs
- **Speaker**: Joseph Jordan, PharmD, Drug Information Specialist
- **Credit**: 2
- **Timing**: 8:45-10:45
- **Objectives**:
  1. Identify new drugs approved by the FDA in 2017 and early 2018, including their indications and potential off label uses.
  2. Recognize the clinically relevant drug interactions, common adverse effects, monitoring parameters, contraindications and precautions of new drugs.
  3. Compare and Contrast to other members of the therapeutic classes.

### Break
- **Timing**: 10:45-11:00

### Hypertension Tension
- **Title**: Hypertension Tension
- **Speaker**: Julie Koehler, PharmD, FCCP, Associate Dean for Clinical Education & External Affiliations and Tracy Sprunger, PharmD, Associate Professor of Pharmacy Practice
- **Credit**: 1
- **Timing**: 11:00-12:00
- **Objectives**:
  1. Outline the most recent guideline update for hypertension.
  2. Compare and contrast major recommendation changes to previous guidelines.
  3. Apply updated guidelines to patient scenarios.
Lunch

12:00 - 12:30

Antiepileptic Medications: A Review
JA0000358-9999-18-011-L01-P

Lauren Czosnowski, PharmD, BCPS, Associate Professor of Clinical Pharmacy and Elizabeth Gill, PharmD, Assistant Professor of Pharmacy Practice

2

12:30-2:30

1. Outline pathophysiology and classification of seizures.
2. Identify antiepileptic drugs (AEDs) used in treatment of seizures.
3. Review appropriate drug monitoring and dosage adjustments required with AEDs.
4. Discuss the use of CBD products for patients with seizures.

Break

2:30 - 2:45

Piecing Together the Puzzle of ADHD
JA0000358-9999-18-011-L01-P

Jake Peters, PharmD, BCPP, BCPS, Assistant Professor of Pharmacy Practice

2

2:45-4:45

1. Discuss the definition, sub-types, epidemiology, prevalence and etiology of attention-deficit/hyperactivity disorder (ADHD).
2. Outline key features of stimulant and non-stimulant medication products.
3. Identify common side effects, potential drug interactions, and methods to mitigate risk for diversion and misuse of commonly prescribed ADHD medications.
4. Apply knowledge of ADHD medications to patient scenarios.

Wrap up

4:45-5:00

Carriann Smith, PharmD, Associate Professor of Pharmacy Practice
<table>
<thead>
<tr>
<th>Title</th>
<th>Speaker</th>
<th>Credit</th>
<th>Timing</th>
<th>Objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>June 8, Day 2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Introduction and CPE credit requirements</td>
<td>Carriann Smith, PharmD, Associate Professor of Pharmacy Practice</td>
<td></td>
<td>7:45-8:00</td>
<td></td>
</tr>
<tr>
<td>The ABCs of Pharmacoeconomics</td>
<td>Prachi Arora, PhD, Assistant Professor of Pharmacy Practice</td>
<td>1/2</td>
<td>8:00-8:30</td>
<td>1. Define Pharmacoeconomics (PE) and principles of a PE analysis. 2. Discuss the different methodologies of PE analysis &amp; their applications in healthcare.</td>
</tr>
<tr>
<td><strong>Break</strong></td>
<td></td>
<td></td>
<td>8:30-8:45</td>
<td></td>
</tr>
<tr>
<td>New Drugs 2: Biologics</td>
<td>Joseph Jordan, PharmD, Drug Information Specialist</td>
<td>2</td>
<td>8:45-10:45</td>
<td>1. Review the definition of biologics and factors related to bio-similarity. 2. Identify new biologics approved by the FDA in 2017 and early 2018, including their indications and potential off label uses. 3. Recognize the clinically relevant interactions, common adverse effects, monitoring parameters, contraindications and precautions of new biologics.</td>
</tr>
<tr>
<td><strong>Break</strong></td>
<td></td>
<td></td>
<td>10:45-11:00</td>
<td></td>
</tr>
<tr>
<td>To the point: Counseling patients with dyslipidemia</td>
<td>Kacey Carroll, PharmD, BCGP, BCACP, Assistant Professor of Pharmacy Practice</td>
<td>1</td>
<td>11:00-12:00</td>
<td>1. Review dyslipidemia and atherosclerotic cardiovascular disease. 2. Outline treatment guidelines for patients with dyslipidemia. 3. Discuss appropriate use of pharmacologic treatment for dyslipidemia. 4. Provide counseling pearls for patients receiving treatment for dyslipidemia.</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker(s)</td>
<td>Notes</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 12:00-12:30 | **Voyage Through the “C”: Overview of Hepatitis C Management**          | Brooke Stevens, PharmD, BCPS, AAHIVP Clinical Pharmacist – HIV/HCV Indiana University Health | 1. Outline the epidemiology of hepatitis C (HCV) infection.  
2. Describe the screening process and follow-up testing utilized for HCV.  
3. Identify appropriate treatment regimens for HCV based on patient- and disease-related variables.  
4. Discuss the role of pharmacists in the management of HCV. |
| 12:30-2:30 | **Break**                                                               |                                                                           |                                                                                                                                     |
| 2:30-2:45  | **Addressing the Unique Challenges Associated with Continued Antipsychotic Use** | Laura Ruekert, PharmD, BCPP, BCGP, Associate Professor of Pharmacy Practice | 1. Explain the use of different antipsychotics in various mental health conditions  
2. Outline adverse effects associated with continued antipsychotic use  
3. Discuss strategies associated with maintaining access and adherence in the mental health population |
| 2:45-3:45  | **Taking a Shot at Alcohol Use Disorder**                               | Jake Peters, PharmD, BCPP, BCPS, Assistant Professor of Pharmacy Practice | 1. Outline the pathophysiology, diagnosis, and clinical course of addiction as it relates to alcohol use disorder (AUD).  
2. Review the treatment modalities currently available for management of AUD.  
3. Apply the knowledge of treatment options to patient scenarios.  
4. Outline strategies for improving therapeutic adherence in patients treated for AUD. |
| 3:45-4:45  | **Wrap up**                                                             | Carriann Smith, PharmD, Associate Professor of Pharmacy Practice          |                                                                                                                                     |